APC302

About AdjuTec Pharma

AdjuTec Pharma is a private, preclinical-stage biotech founded in 2019, originating from research at the University of Oslo. The company is developing adjuvant therapies, specifically β-lactamase inhibitors, designed to break bacterial resistance and rescue last-line antibiotics like carbapenems and cephalosporins. Its lead candidate, APC148, has completed a First-In-Man study, positioning the company to tackle a critical and growing global health crisis. Backed by private funding, public grants, and a founding professor-emeritus as its largest shareholder, AdjuTec aims to bring its novel resistance-breaking combinations to market.

Therapeutic Areas